Percutaneous ablation plus transarterial chemoembolization versus TACE in hepatocellular carcinoma received regorafenib treatment: a retrospective cohort study

Background Regorafenib serves as the second-line systemic therapy for unresectable hepatocellular carcinoma (uHCC), the clinical value of combining locoregional treatments to boost its antitumor efficacy remains under active investigation. Objectives This study aimed to explore whether adding percutaneous ablation to TACE plus regorafenib (A+T+R) yields superior clinical outcomes compared with TACE combined with regorafenib (T+R) in uHCC. Methods This study retrospectively screened consecutive patients with uHCC who received regorafenib between July 2020 and September 2024, with the final follow-up cutoff date set as December 31, 2024. Enrolled patients received either the A+T+R or T+R treatment regimen. Propensity score matching (PSM) was performed to reduce baseline selection bias. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective tumor response, disease control and treatment safety. Results A total of 162 eligible patients were enrolled (77 in the A+T+R group and 85 in the T+R group). After PSM, 46 patients remained in each group. Median PFS was comparable between the two cohorts before and after PSM (pre-PSM: 8.4 vs. 6.6 months, P = 0.084; post-PSM: 8.1 vs. 6.9 months, P = 0.301). By contrast, this significant OS benefit persisted after PSM adjustment as well (pre-PSM: 41.6 vs. 13.9 months, P < 0.001; post-PSM: 41.6 vs. 17.7 months, P = 0.022). The most common any-grade TRAE in both groups was elevated AST (62.3% vs. 45.9%). Before PSM, AST elevation was more frequent in the A+T+R group than in the T+R group ( P = 0.041); however, this difference was no longer significant after PSM ( P = 0.193). Conclusion Compared with TACE plus regorafenib, triple therapy consisting of percutaneous ablation, TACE and regorafenib was associated with longer OS with an acceptable safety profile in patients with uHCC after first-line treatment failure. However, the observed OS difference cannot be definitively attributed to percutaneous ablation given potential residual confounding. These findings should be interpreted cautiously and require further validation in prospective studies.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.1946827
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Percutaneous ablation plus transarterial chemoembolization versus TACE in hepatocellular carcinoma received regorafenib treatment: a retrospective cohort study

songtao liu, Jingjing Chen, Mei Liu, Yang Wang et al.
4 links
Frontiers in Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Percutaneous ablation plus transarterial chemoembolization versus TACE in hepatocellular carcinoma received regorafenib treatment: a retrospective cohort study

songtao liu, Jingjing Chen, Mei Liu, Yang Wang, Jinhuan Wang
article en

Abstract

Background Regorafenib serves as the second-line systemic therapy for unresectable hepatocellular carcinoma (uHCC), the clinical value of combining locoregional treatments to boost its antitumor efficacy remains under active investigation. Objectives This study aimed to explore whether adding percutaneous ablation to TACE plus regorafenib (A+T+R) yields superior clinical outcomes compared with TACE combined with regorafenib (T+R) in uHCC. Methods This study retrospectively screened consecutive patients with uHCC who received regorafenib between July 2020 and September 2024, with the final follow-up cutoff date set as December 31, 2024. Enrolled patients received either the A+T+R or T+R treatment regimen. Propensity score matching (PSM) was performed to reduce baseline selection bias. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective tumor response, disease control and treatment safety. Results A total of 162 eligible patients were enrolled (77 in the A+T+R group and 85 in the T+R group). After PSM, 46 patients remained in each group. Median PFS was comparable between the two cohorts before and after PSM (pre-PSM: 8.4 vs. 6.6 months, P = 0.084; post-PSM: 8.1 vs. 6.9 months, P = 0.301). By contrast, this significant OS benefit persisted after PSM adjustment as well (pre-PSM: 41.6 vs. 13.9 months, P < 0.001; post-PSM: 41.6 vs. 17.7 months, P = 0.022). The most common any-grade TRAE in both groups was elevated AST (62.3% vs. 45.9%). Before PSM, AST elevation was more frequent in the A+T+R group than in the T+R group ( P = 0.041); however, this difference was no longer significant after PSM ( P = 0.193). Conclusion Compared with TACE plus regorafenib, triple therapy consisting of percutaneous ablation, TACE and regorafenib was associated with longer OS with an acceptable safety profile in patients with uHCC after first-line treatment failure. However, the observed OS difference cannot be definitively attributed to percutaneous ablation given potential residual confounding. These findings should be interpreted cautiously and require further validation in prospective studies.

Frontiers in OncologyVol. 16
Capital Medical University (CN), Beijing YouAn Hospital (CN)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon